Ligand News and Research

RSS

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

17 Oct 2013

Pieris Inks Co-Development Deal With Zydus For Protein Drugs

...

16 Oct 2013

Pieris Inks Co-Development Alliance With Zydus For Protein Drugs

...

16 Oct 2013

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and Pieris AG, a next generation therapeutic protein R&D company, have entered into an alliance for development and commercialization of multiple novel Anticalin-based protein therapeutics, both companies announced today.

16 Oct 2013

Genetic mutation that protects skin from UV radiation may cause testicular cancer in Caucasian

A Ludwig Cancer Research study published in Cell today identifies a common mutation that dramatically increases the risk for testicular cancer—and describes a likely molecular mechanism by which it exerts that effect.

11 Oct 2013

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.

30 Sep 2013

Study: Antidepressant drugs prove to be effective against SCLC patients

A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

27 Sep 2013

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

...

24 Sep 2013

Innovative system can help manipulate stem cells to repair damaged tissues and organs

Scientists know that physical and biochemical signals can guide cells to make, for example, muscle, blood vessels or bone. But the exact recipes to produce the desired tissues have proved elusive.

19 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody product to enter the clinic this year.

17 Sep 2013

Researchers find mucus-regulating protein receptors out of control in uterine, pancreatic cancers

A "vicious cycle" produces mucus that protects uterine and pancreatic cancer cells and promotes their proliferation, according to researchers at Rice University. The researchers offer hope for a therapeutic solution.

17 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

Dunking in tub of ice water post-exercise decreases strength, soreness

Dunking in a tub of ice water after exercise - a surprisingly popular post-workout regimen used by athletes to reduce inflammation and speed recovery - is time consuming and bone-achingly painful. New research from the University of New Hampshire finds that it may not be effective, either.

20 Aug 2013

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

STED-RICS microscopy method records rapid movements of molecules in live samples

The newly developed STED-RICS microscopy method records rapid movements of molecules in live samples. By combining raster image correlation spectroscopy (RICS) with STED fluorescence microscopy, researchers of Karlsruhe Institute of Technology (KIT) opened up new applications in medical research, e.g. analyzing the dynamics of cell membranes at high protein concentrations.

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Ligand News and Research

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Pieris Inks Co-Development Deal With Zydus For Protein Drugs

Pieris Inks Co-Development Alliance With Zydus For Protein Drugs

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Genetic mutation that protects skin from UV radiation may cause testicular cancer in Caucasian

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

Study: Antidepressant drugs prove to be effective against SCLC patients

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

Innovative system can help manipulate stem cells to repair damaged tissues and organs

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

Researchers find mucus-regulating protein receptors out of control in uterine, pancreatic cancers

Roche Signs Up To $422.5M Collaboration With Inovio

Dunking in tub of ice water post-exercise decreases strength, soreness

Ensemble Therapeutics initiates research and development collaboration with Novartis

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

STED-RICS microscopy method records rapid movements of molecules in live samples

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News